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As propriedades da prata são conhecidas há muitos anos. Recentemente, as nanopartículas de 
prata têm chamado a atenção por sua atividade antimicrobiana que oferece a possibilidade de uso 
com propósitos médicos e de higiene. Estas nanopartículas de prata em diferentes formulações, 
com diferentes formas e tamanhos, exibem atividades antimicrobianas diferentes. Entretanto, os 
mecanismos da atividade antimicrobiana de íons e de nanopartículas, assim como sua toxicidade 
em tecidos humanos não estão totalmente esclarecidos. Esta revisão avalia o uso potencial de 
nanopartículas de prata no controle de patogênicos com ênfase sobre sua ação contra bactérias 
patogênicas, sua toxicidade e possíveis mecanismos de ação.
The antimicrobial properties of silver have been known for thousands of years. Recently, 
silver nanoparticles have gained attention because of their antimicrobial activity which offers the 
possibility of their use for medical and hygiene purposes. Indeed, silver nanoparticles in different 
formulations and with different shapes and sizes exhibit variable antimicrobial activity. However, 
the mechanisms of antimicrobial activity of silver ions and silver nanoparticles, and their toxicity 
to human tissues are not fully characterized. This review evaluates the potential use of silver 
nanoparticles to control pathogens with emphasis on their action against pathogenic bacteria, their 
toxicity and possible mechanisms of action. 
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1. Introduction
There is a growing concern about the emergence and 
re-emergence of drug-resistant pathogens such as multi-
resistant bacterial strains, fungi and parasites.1 Therefore, 
the development of new antimicrobial compounds or 
the modification of those available in order to improve 
antimicrobial activity for therapy, antisepsis or disinfection is a 
high priority area of research. In this endeavor, nanotechnology 
provides a means to modify key features of different 
materials, including metal nanoparticles.2,3 The inhibitory and 
bactericidal activities of silver ions have long been known.4-7 
Some forms of silver have been demonstrated to be effective 
against burn infections, severe chronic osteomyelitis, urinary 
tract infections and central venous catheter infections.8 
Based on these results, many silver-based antimicrobial 
materials have become available and several others are 
under development in research laboratories.2,9 In addition to 
antimicrobial activity, the mechanisms of action and toxicity 
are also of paramount importance and several studies are under 
way to better elucidate these aspects. 
Metallic nanoparticles can be obtained by physical, 
chemical or biological methods. However, biological 
synthesis is reliable and eco-friendly, and has received 
particular attention. In fact, a number of different species of 
bacteria and fungi are able to reduce metal ions producing 
metallic nanoparticles with antimicrobial properties.10-16 
Recently, efficient antibacterial activity was observed 
against multidrug resistant and highly pathogenic bacteria, 
including multidrug resistant Staphylococcus aureus, 
Salmonella typhi, Staphylococcus epidermidis and 
Escherichia coli by silver nanoparticles produced by the 
fungus F. acuminatum.17 Additionally, plant extracts can 
also be used to obtain metallic nanoparticles.18,19 
This review discusses the current worldwide research 
on the use of silver nanoparticles to fight pathogenic 
microorganisms. It focuses on anti-microbial activities, 
silver nanoparticle/antibiotic association and toxicity. 
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2. Silver Nanoparticles Biological Activities 
2.1. Antibacterial and bactericidal activities
The inhibitory effect of silver is probably the sum 
of distinct mechanisms of action. A number of studies 
suggest that silver ions react with SH groups of proteins20,21 
and play an essential role in bacterial inactivation.7 
Micromolar levels of silver ions have been reported to 
uncouple respiratory electron transport from oxidative 
phosphorylation, which inhibits respiratory chain enzymes 
or interferes with membrane permeability to protons and 
phosphate.21 Studies conducted by Feng et al.21 and by Jung 
et al.22 have shown the activity of silver ions on Escherichia 
coli (Gram-negative) and Staphylococcus aureus (Gram-
positive), respectively. Feng et al.21 treated these bacteria 
with AgNO
3
 and studied the effects on cell morphology 
using combined electron microscopy (TEM and SEM) 
and X-ray microanalyses. E. coli and S. aureus underwent 
similar morphological changes after silver ion treatment 
characterized by a cytoplasm membrane detachment from 
cell walls and the appearance of an electron-light region 
in the center of the cells, which contained condensed 
deoxyribonucleic acid (DNA) molecules probably formed 
to protect DNA from injuries mediated by the silver ions. 
Small electron-dense granules either surrounding the cell 
wall or deposited inside the cells were also present.21 
Recently, Jung et al.22 reported results corroborating the 
morphological changes described by Feng et al.21 and also 
suggested that in the presence of silver ions, bacterial cells 
reach an active but non-culturable state and eventually 
die. Jung et al.22 also suggested that the thickness of the 
peptidoglycan layer of gram-positive bacteria may prevent 
to some extent, the action of the silver ions, since they found 
a higher inhibitory activity of silver ion solution against 
E. coli than against S. aureus which also corroborates the 
conclusion of Feng et al.21
The presence of silver ions and sulfur in the electron-
dense granules observed after silver ions treatment in the 
cytoplasm of bacterial cells suggests an interaction with 
nucleic acids that probably results in impairment of DNA 
replication.21
Silver ions and silver nanoparticles also have inhibitory 
and lethal effects on bacterial species such as E. coli,9,23-25 
S. aureus9 and even yeast.9 In the last paper, the authors 
have prepared silver nanoparticles by mixing silver 
nitrate with sodium borohydride to obtain particles that 
were highly monodispersed with an average diameter of 
13.5 ± 2.6 nm. They have observed that yeast and E. coli 
were inhibited at low concentrations of nanoparticles, 6.6 
and 3.3 nmol L-1, respectively, whereas the growth-inhibitory 
activity on S. aureus was mild, with the minimal inhibitory 
concentration (MIC) estimated to be higher than 33 nmol L-1. 
This study also suggested that the generation of free-radicals 
is involved in some way with the antimicrobial activity of 
silver nanoparticles. In fact, oxidative stress was observed 
in cells after silver nanoparticles interaction.26 However, 
results described by Lok et al.27 differ in some way with those 
obtained by Kim et al.9 regarding the involvement of free-
radicals in the antimicrobial activity of silver nanoparticles. 
Further studies are therefore required in order to clarify the 
exact role of free-radicals.
Raffin et al.28 observed that silver nanoparticles with 
mean sizes of 16 nm were completly cytotoxic for E. coli 
at a low concentration (60 mg mL-1). The assay was carried 
out in liquid and solid growth media and was verified 
by transmission electron microscopy (TEM). Silver 
nanoparticles were observed to adhere to the cell wall and 
were also found inside the bacteria. Gade et al.29 produced 
silver nanoparticles by extracellular biosynthesis using 
Aspergillus niger isolated from soil. Particles with 20 nm 
were cytotoxic to E. coli and TEM analysis indicated the 
complete disruption of the bacterial membrane after few 
minutes in contact with silver nanoparticles. This result 
shows the high efficiency of silver nanoparticles due to the 
large surface area available for interactions.28
Morones et al.7 tested the activity of silver nanoparticles 
in E. coli, Vibrio cholerae, Pseudomoma aeruginosa and 
Salmonella enterica Typhi (all species of Gram-negative 
bacteria). Release of silver nanoparticles in powder form 
from a carbon matrix showed a large size distribution. Only 
individual particles were observed to be attached to the 
surface of the bacterium membrane. The mean size of these 
silver nanoparticles interacting with bacteria was 5 ± 2 nm. 
Particles were found in the bacteria membrane and inside 
the cells. The particles sizes in the membrane and inside 
the cells were similar, suggesting that the particles that 
interact with the membrane are able to invade the bacteria. 
Furthermore, particles penetration was size dependent. 
Particles with sizes between 1-10 nm interact preferentially 
with bacteria. This particle penetration ability was also 
verified by Sondi and Salopek-Sondi.23 In this study was 
observed an accumulation of silver nanoparticles on the 
E. coli cell membranes, while some penetrated into the 
cells. This difference in silver nanoparticle distribution in 
the cell can be due to particle size. 
The comparison of the antimicrobial effect of silver 
ions and silver nanoparticles is an interesting field of 
research and some studies were performed in this direction. 
Morones et al.7 showed that the overall effect of the silver 
nanoparticles was different from the effect of only silver 
ions. When nanoparticles were used in this study, no 
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evidence was found for the formation of a low density 
region as reported previously by Feng et al.21 for silver ions. 
Instead, a large number of small silver nanoparticles were 
observed inside the bacteria. The results of Morones et al.7 
also indicate that silver ions present in the nanoparticle 
solution contributed but it is not the sole mechanism of 
antimicrobial activity induced by nanosilver.
Recently, proteomic analysis revealed that even a short 
exposure of silver nanoparticles to E. coli cells resulted 
in alterations in the expression of a panel of envelope 
and heat shock proteins.30 Therefore, these particles can 
penetrate and can disrupt the membranes of bacteria. A 
massive loss of intracellular potassium was induced by 
silver nanoparticles. Furthermore, the silver nanoparticles 
decreased the ATP levels. Both effects may culminate in 
the loss of cell viability. Similar results were observed 
with silver ions.30 However, the major difference between 
silver nanoparticles and silver ions is on their effectiveness 
against bacteria, which are at nanomolar concentrations 
in the case of nanoparticles and in the micromolar ranges 
in the case of silver ions. The possible molecular targets 
for these silver species could be protein thiol groups (key 
respiratory enzymes).The phospholipid portion of the 
bacterial membrane may also be the site of action for the 
silver species.30
A pivotal matter of the employment of silver species 
as antimicrobial agents is the selection of resistant 
microorganisms. Although clinical incidence of silver 
resistance remains scarce, this resistance can increase due to 
the great number of products with silver that liberate silver 
ions into the environment.31 Silver32 described the resistance 
mechanisms against silver ions exhibited by bacteria in 
detail at the molecular level. Resistant microorganisms 
are present in environments where silver salts (e.g., silver 
nitrate, silver sulfadiazine) are used as antiseptics, such 
as in burn wards of hospitals. Chromosomic or plasmidial 
genes responsible for silver resistance have been studied by 
molecular techniques. For instance, silver ion resistance in 
Salmonella enterica is mediated by nine genes organized 
in three transcription units present in plasmid pMGH100. 
A sensor/responder, two-component transcriptional 
regulatory system governs synthesis of a periplasmic 
silver ion-binding protein together with two efflux pumps, 
a P-type ATPase plus a three-protein chemiosmotic silver 
ion/H+ exchange system. The centrally located six genes of 
this operon were found and were functional in the genome 
of other bacteria including different strains of E. coli.32,33
A recent synthesis of silver nanoparticles using 
a reduction of aqueous silver ions with the culture 
supernatants of Staphylococcus aureus was reported. The 
silver nanoparticles were evaluated for their antimicrobial 
activities against different pathogenic organisms. The 
highest sensitive antimicrobial activity was observed 
against Methicillin resistant Staphylococcus aureus 
(MRSA) followed by Methicillin resistant Staphylococcus 
epidermidis (MRSE) and Streptococcus pyogenes; while 
with Salmonella typhi and Klebsiella pneumoniae moderate 
antimicrobial activity was observed.34
2.2. Antimicrobial activities and silver nanoparticle size 
and shape
Recent results suggest that silver nanoparticles undergo 
a shape-dependent interaction with the bacterial cells. 
Pal et al.35 demonstrated that truncated triangular silver 
nanoplates displayed the strongest biocidal action against 
E. coli, when compared with spherical and rod-shaped 
nanoparticles and also with silver ions. Similar conclusions 
were reached by Sharma et al.36
The size of the particle plays a central role in 
antimicrobial activity. In a recent study, colloidal silver 
particles, with variable sizes (44, 50, 35, and 25 nm), 





with carbohydrates were tested for antimicrobial activity. 
The antibacterial activity was particle size dependent. 
Small particles exhibited higher antimicrobial activity 
than big particles.37 This result can be due to high particle 
penetration when these particles have smaller sizes.7 In 
another study, the antibacterial activity towards E. coli 
of gel hybrids containing silver nanoparticles of different 
sizes, i.e., 2.67 nm, 6.63 nm, and 21.11 nm, were examined 
and compared with silver nanoparticles (ca. 220 nm) 
without any stabilization. The results showed that the silver 
nanoparticles of 2.67 nm protected by hydrogel polymer 
chains present an excellent antibacterial activity compared 
to the larger sized silver nanoparticles in the hybrid 
networks.25 These authors concluded that the lower sized 
nanoparticles in the hydrogel probably diffused more easily 
than the larger ones, which explains the higher toxicity on 
the E. coli strain used in this study. 
The influence of size on antimicrobial activity was also 
investigated by Baker et al.6 In this study, the antibacterial 
properties were related to the total surface area of the 
nanoparticles. Smaller particles with larger surface to 
volume ratios have greater antibacterial activity. Similar 
results were published by Choi and Hu.38
The synthesis of silver nanocrystals encapsulated in 
mesoporous silica nanoparticles with a yolk/shell structure 
has been described, and demonstrate their antimicrobial 
effect. A complete inhibition of bacterial growth was 
reached with 100 mg mL-1 of the particles. These silver-
containing nanoparticles may be used as a promising 
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alternative to the current technologies involving the use 
of silver nanoparticles and silver-doped materials as 
antimicrobial coatings and colloidal suspensions.39
2.3. Silver nanoparticles and antibiotics
The association of metal nanoparticles and antibiotics 
is a very promising area of research. Nanosilver particles 
are interesting when compared with silver ions due to their 
larger size, which, in turn, improves the capacity to react 
with several molecules. In fact, larger chelated compounds 
can produce different antimicrobial effects and even a 
synergistic antibacterial effect has been observed.40 In 
this study, the bactericidal action of silver nanoparticles 
and amoxicillin was investigated using E. coli as a model 
and silver nanoparticles of 20 nm in size (prepared by 
reducing an aqueous solution of AgNO
3
 with a freshly 
prepared aqueous ascorbic acid solution and ammonia). 
Microbiological tests confirm that combining amoxicillin 
with silver nanoparticles results in a synergistic antibacterial 
effect on E. coli cells. In this study, the amount of 5 mg mL-1 
of silver nanoparticles caused no obvious effect on bacterial 
growth and 0.15 mg mL-1 of amoxicillin caused a minor 
delay in the growth, but the combination of these drugs in 
these same concentrations caused a significant reduction of 
growth, which can probably be explained by the synergistic 
action of these two antimicrobial compounds. 
To explain the mechanism of this synergistic antibacterial 
effect, Li et al.40 proposes that silver nanoparticles and 
amoxicillin exhibit different mechanisms of action 
(Figure 1). Moreover, the synergism is probably caused 
by a binding reaction between amoxicillin and silver 
nanoparticles, since amoxicillin molecules exhibit groups 
such as hydroxyl and amido groups that can react easily 
with silver nanoparticles. The authors did not mention 
the sulfur bridge in the molecule that probably is the 
most important binding site with the silver nanoparticles. 
Therefore, in addition to its antimicrobial activity, the silver 
nanoparticles probably operate as an antibiotic carrier. 
The availability of biosynthetically produced silver 
nanoparticles10,41-44 opens the possibility to investigate the 
association of these biological particles with antibiotics. A 
recent study was carried out with clindamycin and silver 
nanoparticles produced chemically or biosynthetically 
(Figure 2).45 The silver nanoparticles were chemically 
associated with clindamycin and purified before being used 
as an antibacterial compound (Figure 3). Preliminary results 
with these two formulations conducted in the presence of 
several bacteria, such as methicillin-resistant S. aureus strains 
(MRSA) and Staphylococcus epidemidis showed a significant 
bactericidal activity of both formulations with slightly lower 
MIC values observed with the biosynthetic nanoparticles. 
However, this activity was dependent upon the bacterial 
strain analyzed and also on the size of the nanoparticles. In 
addition, the biosynthetically produced nanoparticles were 
more stable than the chemical ones.45 Beside this, a study on 
the effect of silver nanoparticles associated with clindamycin 
on leishmaniasis was published.46
Recently, the combination of the silver nanoparticles 
with different antibiotics was investigated for activity 
Figure 1. Structure of amoxicillin and the bonding route for silver nanoparticles chelated with amoxicillin and a diagram of the combination of chelate 
reacted with cells (Adapted from reference 40).
Durán et al. 953Vol. 21, No. 6, 2010
against S. aureus and E. coli. The antibacterial activities 
of penicillin G, amoxicillin, erythromycin, clindamycin, 
and vancomycin increased in the presence of silver 
nanoparticles against both tested bacterial strains.47 
Also, nineteen antibiotics were recently studied for 
antimicrobial activity in combination with the Silver-
Water DispersionTM solution (15 nm diameter silver 
nanoparticles clusters containing silver ions produced by 
an electro-colloidal silver process). The minimal inhibitory 
concentrations were determined for the antibiotics and 
in combination with the Silver-Water DispersionTM 
solution (De Souza et al.).48 This study evaluated the 
susceptibility of Gram-positive and Gram-negative bacteria 
strains such as multiple-drug resistant (MDR) E. coli, 
S. aureus, Salmonella enterica Typhi, Shigella flexineri 
and Bacillus subtilis. Based on the results for amoxicillin 
and clindamycin, as examples, experiments measuring the 
effect of association between Silver-Water Dispersion with 
amoxicillin showed an additive effect on S. aureus 6538 P 
strain, S. enterica Typhi, S. flexneri and B. subtilis but an 
antagonistic effect was observed with a meticillin-resistant 
S. aureus strain (MRSA). On the other hand, the results 
with clindamycin showed only additive effect on MRSA, 
S. aureus 6538 P, S. flexneri and B.subtilis.48 
Several antibiotics such as ampicillin, gentamycin, 
kanamycin, streptomycin and vancomycin were tested with 
silver nanoparticles produced from Phoma glomerata. The 
antibacterial activities of these antibiotics were increased 
in combination with silver nanoparticles against the Gram-
negative micro-organisms, i.e., E. coli and Pseudomonas 
aeruginosa, as compared with Staphylococcus aureus 
as a better synergistic activity was observed with E. coli 
and Pseudomonas aeruginosa than with Staphylococcus 
aureus.49
These syntheses of norvancomycin-capped silver 
nanoparticles and their in vitro antibacterial activities 
Figure 2. Diagram of the silver nanoparticles formation by fungi (Adapted from reference 10).
Figure 3. Structures and diagram of the complex between clindamycin and silver nanoparticles produced by chemical and biologically methods. 
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against E. coli were recently studied. Mercaptoacetic acid-
stabilized spherical silver nanoparticles with a diameter of 
16 ± 4 nm were prepared. The TEM images of single bacteria 
treated with these nanoparticles showed aggregation in the 
cell wall of E. coli. A possible antibacterial mechanism 
was proposed where silver nanoparticles could destroy the 
stability of the outer membrane of E. coli, which makes 
the silver nanoparticles easier to bind to the lower part of 
the peptidoglycan structure.50 
A study on silver nanoparticles as an active carrier for 
chloramphenicol (CHL) in polyvinylpyrrolidone (PVP) 
has been published. PVP plays a dual role in such studies 
wherein it acts as a stabilizing agent as well as a link for 
binding the CHL to the silver nanoparticles. The percentage 
loading of the drug onto the silver nanoparticles was found 
to be 81%. The drug-loaded silver nanoparticles showed 
substantially enhanced activity against clinically isolated 
S. typhi, thus showing considerable promise for further 
development.51 
These data are indicative that the association of silver 
nanoparticles with antibiotics is a very promising strategy 
to control antimicrobial resistant bacteria. Questions such 
as differences between the pre-formulated nanoparticles 
bound to the antibiotics versus the simultaneous addition 
of the silver nanoparticles and the antibiotics as well as the 
comparison of silver nanoparticles produced chemically or 
biosynthetically, merit more profound investigation.
2.4. Toxicity
The results described above indicate the beneficial 
impact of metallic nanoparticles on human health. However, 
some studies indicate that certain nanoparticles may cause 
adverse effects due to their small size and properties.45,52,53 
The small size makes them highly mobile both in the 
human body and the environment.54 Nanoparticles can 
gain access to the body by inhalation,55 by oral ingestion 
(Jani et al.,56 1990) and probably by contact with the skin.57 
After uptake, nanoparticles can disseminate to different 
body tissues.58-61 However, few toxicology studies are 
presently available.
Burd et al.62 studied the cytotoxicity of five commercially 
available dressings on the market containing silver ion or 
metallic nanocrystalline silver: Acticoat™, Aquacel® Ag, 
Contreet® Foam, PolyMem® Silver and Urgotul®SSD. All 
dressings were pretreated with different solutions and the 
cytotoxicity assay was performed. The study confirmed 
that the cytotoxicity was dependent on the dressing and 
on the concentration of silver in the pretreatment solution. 
The cytotoxicity in various cultures such as a monolayer 
cell culture, a tissue explant culture model and a mouse 
expurgated wound model was also studied. The results 
showed that c, Aquacel® Ag and Contreet® Foam presented 
the most significant cytotoxic effects in keratinocyte and 
fibroblast cultures.
Recently, ActicoatTM was used in post-cardiac surgery 
mediastinitis using a recently introduced silver-releasing 
dressing claiming prompt antibacterial activity. In all four 
patients negative cultures were obtained within a maximum 
of 72 h and patients were discharged within a maximum 
of 20 days.63
Hussain et al.64 evaluated the acute toxicity of different 
metallic nanoparticles in vitro using a rat liver derived cell 
line (BRL 3A) (ATCC, CRL-1442 immortalized rat liver 
cells). Different sizes of silver nanoparticles (15 or 100 nm) 
were evaluated for their potential toxicity. Exposure to 
silver nanoparticles for 24 h resulted in dose-dependent 
cytotoxicity. Mitochondrial function decreased significantly 
in cells exposed to the nanoparticles and cells treated with 
higher doses of particles exhibited cellular shrinkage and 
irregular shape.64 Cytotoxicity is also dependent on the 
size of the particle. Similar results were recently reported 
for rat neuronal cells exposed to metal nanoparticles. The 
cells presented a decrease in size, an irregular shape and a 
significant dose-dependent impairment of the mitochondrial 
function.26
The toxicity of different types of nanoparticles on 
the C18-4 cells of a mouse cell line with spermatogonial 
stem cell characteristics was evaluated.54 Initially, silver, 
molybdenum, and aluminum nanoparticles with sizes 
of 15, 30 and 30 nm, respectively, were prepared using 
a commercial pulsed-plasma reactor, which forms the 
particles in a gas phase process. Silver nanoparticles were 
the most toxic among the nanoparticle types tested. Phase 
contrast microscopy showed changes induced by silver 
nanoparticles at concentrations starting at 10 mg mL-1. 
Cell apoptosis was also noticed. In general, the inhibition 
of mitochondrial activity increased with the increase of 
the silver nanoparticle concentration. However, for this 
same cell line, silver carbonate showed no significant 
cytotoxic effect on mitochondrial function and cell 
viability up to concentrations of 100 mg mL-1 (EC50 
value of 408 mg mL-1). The results obtained with silver 
carbonate, which was used as a control, were in sharp 
contrast with the cytotoxicity observed with the silver 
nanoparticles, indicating that silver in a nanoparticulated 
form could be toxic to tissues.54 
The cytotoxicity of a wide range of manufactured 
nanoparticulate materials, which were characterized by 
transmission electron microscopy (TEM) and ancillary 
analytical techniques to observe the particle crystallinity, 
was studied using an established cell line of murine alveolar 
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macrophages.65 In this study, chrysotile asbestos was used 
as a positive control. The result indicated an increased 
toxicity for silver versus asbestos. Asbestos has an extreme 
fiber geometry (aspect ratios > 500:1) while the silver is 
characteristically aggregated nanospherules or branched 
nanospherule clusters. The cytotoxicity of these materials 
may be related to their crystallinity since Monarca et al.66 
demonstrated that fine crystalline silica had a more 
detrimental effect in lung epithelial cell damage than fine 
amorphous silica. 
Teeguarden et al.67 have suggested that particokinetics 
and principles of dosimetry would significantly improve 
the basis for nanoparticle toxicity assessment and increase 
the predictive power and scalability of such assays. The 
authors applied particokinetics in the reinterpretation of 
published dose-response data. For instance, they extended 
their analysis by comparing the EC
50
 on a nominal media 
particle surface area/milliliter basis as well as adjusting 
the EC
50
 for approximate delivery from the results 
obtained by Hussein et al.64 It was observed that 15 nm 
silver nanoparticles appear ca. 4000 times less toxic than 
micron-sized cadmium oxide particles on a cm2 mL-1 
media basis, but are only ca. 50 times less toxic when 
differences in delivery to adherent cells were considered. 
The authors concluded that simple surrogates of dose can 
cause significant misinterpretation of response and uptake 
data for nanoparticles in vitro. 
Silver nanoparticles were detected in the lung, liver, 
kidney, spleen, brain, heart, and blood of rats after 
inhalation of ultrafine particles (4-10 nm). In the liver, 
kidney, spleen, brain and heart, low concentrations of 
silver were detected. The level of silver in the liver and in 
the lungs decreased rapidly with time. In blood, significant 
amounts of silver were detected on day 0 and thereafter 
decreased rapidly. Nasal cavities and lung-associated lymph 
nodes showed relatively high concentrations.68 When rats 
received an aqueous suspension of agglomerated ultrafine 
silver particles by intratracheal instillation, a portion 
of the agglomerates remained insoluble in the alveolar 
macrophages and in the septum for at least 7 days, but a 
rapid clearance of instilled water-soluble silver nitrate from 
the lung was observed.68 A possible mechanism for the fast 
clearance is that whereas agglomerated silver nanoparticles 
remain insoluble in alveolar macrophages, ultrafine silver 
nanoparticles were dissolved rapidly in the lung allowing 
silver to enter the blood capillaries by diffusion.68
Toxicity and biocompatibility of silver nanoparticles 
were evaluated in vivo and in real time using zebrafish 
embryos.69 The embryos were treated with spherical silver 
nanoparticles with average diameters of 11.6 ± 3.5 nm 
synthesized by reducing AgClO
4
 with reducing agents 
(sodium citrate and sodium borohydride) and were 
monitored until 120 h post fertilization. The results show 
that a single silver nanoparticle is transported into and 
out of embryos through chorion pore canals and the 
biocompatibility and toxicity of silver nanoparticles and 
types of abnormalities observed in zebrafish are highly 
dependent on the dose of silver nanoparticles, with a 
critical concentration of 0.19 nmol L-1. Following the same 
methodology results with zebrafish suggested that silver 
nanoparticles induce a dose-dependent toxicity in embryos, 
which hinders normal development.70
The short-term toxicity of silver nanoparticles and 
ionic silver (Ag+) to photosynthesis in Chlamydomonas 
reinhardtii was examined. Silver nanoparticles ranged 
in size from 10 to 200 nm with most particles around 
25 nm and about 1% of the silver nanoparticles were 
present as silver ions. Based on total silver concentration, 
toxicity was 18 times higher for AgNO
3
 than for silver 
nanoparticles. It was verified that 1% of total Ag in silver 
nanoparticles was present as Ag+ ions. Thus, the toxicity 
of silver nanoparticles, as a function of the free silver 
ions concentration, was much higher than that of AgNO
3
. 
Furthermore, it was verified that silver nanoparticles 
toxicity is mediated by silver ions. All the results indicate 
that the interaction of these particles with algae influences 
the toxicity of silver nanoparticles through silver ion 
formation in the algal interface. Therefore, the particles 
contributed to the toxicity as a source of silver ions which 
was formed in the presence of algae.71
Panyala et al.72 have summarized the hazardous 
effects of silver nanoparticles in the environment and 
their toxic effects on human health. Biodistribution, 
organ accumulation, degradation, possible adverse effects 
and toxicity as well as major questions associated with 
the increased medical use of nanosilver and related 
nanomaterials were discussed.73
Toxicity of starch-coated silver nanoparticles was 
studied using normal human lung fibroblast cells 
(IMR-90) and human glioblastoma cells (U251), through 
changes in cell morphology, cell viability, metabolic 
activity, and oxidative stress. A possible mechanism of 
toxicity was proposed which involved disruption of the 
mitochondrial respiratory chain by silver nanoparticles 
leading to production of reactive oxygen species (ROS) 
and interruption of ATP synthesis, which in turn cause 
DNA damage.74
The immunological response of macrophages to 
physically produced pure gold and silver nanoparticles 
(in three different sizes) was investigated in vitro. The 
treatment of either type of nanoparticles at ≥ 10 ppm 
dramatically decreases the population and increases the 
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size of the macrophages. Both nanoparticles enter the cells 
but only gold nanoparticles (especially those with smaller 
diameter) up-regulate the expressions of pro-inflammatory 
genes interlukin-1 (IL-1), interlukin-6 (IL-6), and 
tumor necrosis factor (TNF-a). Transmission electron 
microscopic images show that silver nanoparticles and 
gold nanoparticles are both trapped in vesicles in the 
cytoplasma, but only gold nanoparticles were organized 
into a circular pattern. The authors speculated that part of 
the negatively charged gold nanoparticles might adsorb 
serum protein and enter cells via the more complicated 
endocytotic pathway, which results in higher cytotoxicity 
and immunological response of gold as compared to silver 
nanoparticles.75 
The gene expression in different regions of the mouse 
brain (adult male C57BL/6N mice) was studied by i.p. 
administration of 100 mg kg-1, 500 mg kg-1 or 1000 mg kg-1 
silver nanoparticles (25 nm). The animals were sacrificed 
after 24 h. Total RNA was isolated from each of three brain 
regions (caudate nucleus, frontal cortex, hippocampus) and 
RT-PCR analysis was performed. Through gene expression 
the data suggest that silver nanoparticles may produce 
neurotoxicity by generating free radical-induced oxidative 
stress and by altering gene expression, producing apoptosis 
and neurotoxicity.76
Inflammatory responses and pulmonary function 
changes in rats during 90 days of inhalation exposure to 
silver nanoparticles (18 nm) was studied. Histopathological 
examinations indicated dose-dependent increases in lesions 
related to silver nanoparticle exposure, such as infiltrate 
mixed cell and chronic alveolar inflammation, including 
thickened alveolar walls and small granulomatous lesions. 
Considering all the results together, the decreases in the 
tidal volume and minute volume and other inflammatory 
responses after prolonged exposure to silver nanoparticles 
apparently indicate that nanosized particle inhalation 
exposure can induce lung function changes.77,78
In vitro interactions of 7-20 nm spherical silver 
nanoparticles with primary fibroblasts and primary liver 
cells isolated from Swiss albino mice were studied. Upon 
exposure to silver nanoparticles for 24 h, morphology 
of primary fibroblasts and primary liver cells remained 
unaltered up to 25 μg mL-1 and 100 μg mL-1 silver 
nanoparticles, respectively. Metabolic studies, apoptotic 
processes and morphological transformations clearly 
suggest that although silver nanoparticles seem to enter 
the eukaryotic cells, cellular antioxidant mechanisms 
protect the cells from possible oxidative damage. Besides 
that, they exhibited these properties, in conjunction with 
the finding that primary cells possess much higher silver 
nanoparticle tolerances than the concentration in the 
gel (ca. 20 μg g-1) that is used in the form of a topical 
antimicrobial gel formulation for the treatment of burns 
and wounds, which suggesting a reasonable safety for 
the formulation and warrants further study for possible 
human application.79
Toxicity evaluations of silver nanoparticles of different 
sizes using mitochondrial and cell membrane viability 
along with reactive oxygen species (ROS) were studied. 
After 24 h of exposure, viability measurments significantly 
decreased with increasing dose (10-75 μg mL-1) of silver 
nanoparticles (15 nm and 30 nm). A more than 10-fold 
increase of ROS levels in cells exposed to 50 μg mL-1 silver 
nanoparticles (15 nm) suggested that the cytotoxicity of 
silver nanoparticles is probably mediated through oxidative 
stress. Traditional inflammatory mediators, such as levels 
of cytokines/chemokines, including tumor necrosis 
factor, macrophage inhibitory protein and interleukin-6, 
were released into the culture media and examined. 
After 24 h of exposure to silver nanoparticles (15 nm), a 
significant inflammatory response but no detectable level of 
interleukin-6 was observed. A size-dependent toxicity for 
silver nanoparticles was observed, and it was suggested that 
one predominant mechanism of toxicity could be through 
oxidative stress.80
Cytotoxicity of several coated silver nanoparticles was 
established using the Trypan Blue exclusion assay, and then 
they were mixed with respiratory syncytial virus (RSV) and 
added to HEp-2 cells. The effectiveness of RSV inhibition 
was then evaluated by microscopic examination for syncytia 
formation and by immunofluorescence microscopy. The 
results revealed that poly(N-vinyl-2-pyrrolidone)-coated 
silver nanoparticles, which showed low toxicity to cells 
at low concentrations, inhibited RSV infection by 44%, a 
significant reduction compared to controls, thus appearing 
to be a promising candidate for future RSV treatment 
research in animal models.81
Very recently, ecosystem protection by a biotechnological 
process of an effluent containing silver nanoparticles was 
published.82 In this study, the bacteria Chromobacterium 
violaceum was used as biological filter to capture silver 
nanoparticles released after several washings from cotton 
fabrics impregnated with biological silver nanoparticles. 
After silver nanoparticles capture, the bacteria morphology 
was changed, but the bacteria was still alive. However, the 
morphology was completely restored after a new culture. 
This bacterium efficiently absorbed the particles from the 
wash water, demonstrating an excellent method to remove 
metallic nanoparticles from effluents, avoiding any effect 
to the eco-environment.82
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3. Conclusions
Nanotechnology represents a modern and innovative 
approach to develop and test new formulations based 
on metallic nanoparticles with antimicrobial properties. 
Silver nanoparticles represent a prominent nanoproduct 
with potential application in medicine and hygiene. 
Characteristics of silver nanoparticles such as shape 
and size are important not only for augmenting the 
antimicrobial activity, but also for reducing tissue and 
eukaryotic cell toxicities. The possible risks to human 
health posed by silver nanoparticles and the increased 
entry into the environment, with subsequent spread of 
microbial resistance, are of increasing concern given the 
rise of silver-containing products on the market. Therefore, 
further studies are needed to fully characterize the toxicity 
and the mechanisms involved with the antimicrobial 
activity of these particles. Finally, this is an important 
area of research that deserves all our attention owing to its 
potential application in the fight against multi-drug resistant 
microorganisms. 
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